Eli Lilly And Company Patent Portfolio Statistics

Eli Lilly And Company

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Eli Lilly And Company look like?

Total Applications: 2,219
Granted Patents: 1,367
Grant Index 77.94 %
Abandoned/Rejected Applications: 387 (22.06%)
In-Process Applications: 462
Average Grant Time: 2.51 Years
Average Office Actions: 1.28

Which Technology Area Eli Lilly And Company is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1625 Organic Chemistry 223
1624 Organic Chemistry 183
1626 Organic Chemistry 174
1614 117
1654 Fermentation, Microbiology, Isolated and Recombinant Proteins/Enzymes 84

How many patents are Eli Lilly And Company filing every year?

Year Total Applications
2022 0*
2021 68*
2020 65
2019 55
2018 39

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Eli Lilly And Company in USPTO?

Publication number: US20220025009A1
Application number: 17/494,394

PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.

Publication date: 2022-01-27
Applicant: Eli Lilly And Company
Inventors: Avinash Muppidi

Publication number: US20220017496A1
Application number: 17/478,080

The present invention provides a compound of Formula I.or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Publication date: 2022-01-20
Applicant: Eli Lilly And Company
Inventors: Duane Johnston Richard

Publication number: US20210403902A1
Application number: 17/473,173

Methods for selecting, detecting, and/or enriching peptides that bind a target are provided.

Publication date: 2021-12-30
Applicant: Eli Lilly And Company
Inventors: Afshar Sepideh

How are Eli Lilly And Company’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/494,394 Protein Tyrosine-Tyrosine Analogs And Methods Of Using The Same OPAP Central, Docket
17/478,080 Disubstituted Pyrazole Compounds OPAP Central, Docket
17/473,173 Methods Of Selecting And Detecting Binding Peptides Docketed New Case – Ready for Examination OPAP Central, Docket
17/438,692 Preserved Formulations
17/465,066 Selective Estrogen Receptor Degraders Docketed New Case – Ready for Examination OPAP Central, Docket